A feline patient, 14-year-old MN DSH, has creatinine 2.8,...

Hello. This is Dr. Vasquez. Thank you for providing a detailed snapshot of this feline patient. Chronic kidney disease is a cornerstone of feline internal medicine, and a systematic approach using the IRIS guidelines is crucial for optimal management. Let's break down this case.

IRIS Staging for Your Patient

Based on the provided parameters for your 14-year-old MN DSH:

IRIS Stage (based on Creatinine and SDMA):

* Creatinine: 2.8 mg/dL. The IRIS guidelines place feline creatinine values of 1.6-2.8 mg/dL in Stage II, and 2.9-5.0 mg/dL in Stage III. Your patient's creatinine is at the very high end of Stage II.
* SDMA: 22 µg/dL. The IRIS guidelines place feline SDMA values of 18-25 µg/dL in Stage II, and 25-38 µg/dL in Stage III. Your patient's SDMA is at the high end of Stage II, bordering on Stage III.
* Interpretation: The IRIS consensus states that if SDMA is above the next higher IRIS CKD stage for the patient’s creatinine, the patient should be assigned to the higher IRIS CKD stage. In this case, while the creatinine alone might lean towards high Stage II, the SDMA of 22 µg/dL, combined with the creatinine of 2.8 mg/dL (which is right at the cusp), pushes this patient into IRIS Stage III. The USG of 1.018 further supports impaired concentrating ability consistent with CKD.

Proteinuric Substage (based on UPC):

* UPC: 0.6.
* IRIS classifications for proteinuria in cats are: Non-proteinuric (<0.2), Borderline proteinuric (0.2-0.4), and Proteinuric (>0.4).
* Your patient's UPC of 0.6 clearly falls into the Proteinuric (P) substage.

Hypertensive Substage (based on Blood Pressure):

* Blood Pressure: 170/95 mmHg.
* IRIS classifications for systemic hypertension are: Normotensive (SBP <150 mmHg, DBP <90 mmHg), Borderline Hypertensive (SBP 150-159 mmHg, DBP 90-99 mmHg), Hypertensive (SBP 160-179 mmHg, DBP 100-119 mmHg), and Severely Hypertensive (SBP >180 mmHg, DBP >120 mmHg).
* With an SBP of 170 mmHg, your patient is definitively in the Hypertensive (H) substage.

Conclusion for this patient: This cat is IRIS Stage III, Proteinuric (P), and Hypertensive (H).

Evidence-Based Treatment Protocols by IRIS Stage

The general approach to CKD management involves addressing the primary stage, then layering on interventions for proteinuria and hypertension.

General Management Principles for Each IRIS Stage:

* IRIS Stage I (Creatinine <1.6 mg/dL, SDMA <18 µg/dL):
* Often asymptomatic. Focus on identifying and treating underlying causes (e.g., pyelonephritis, nephrolithiasis, hypercalcemia).
* Regular monitoring (q3-6 months) for progression.
* Consider a renal diet if progression is noted, or if there is concurrent proteinuria or hypertension.
* IRIS Stage II (Creatinine 1.6-2.8 mg/dL, SDMA 18-25 µg/dL):
* Clinical signs are often mild or absent.
* Dietary Management: Introduce a therapeutic renal diet (e.g., Hill's k/d, Royal Canin Renal, Purina ProPlan NF). These diets are phosphorus-restricted, protein-controlled, sodium-restricted, and often supplemented with omega-3 fatty acids and alkalinizing agents.
* Phosphate Management: Monitor serum phosphorus. If consistently elevated (>4.5-5.0 mg/dL), introduce oral phosphate binders (e.g., aluminum hydroxide) mixed with food.
* Hydration: Encourage water intake. Consider supplemental subcutaneous fluids if there's evidence of dehydration or persistent azotemia despite diet.
* Proteinuria/Hypertension: Manage as per substaging guidelines below.
* IRIS Stage III (Creatinine 2.9-5.0 mg/dL, SDMA 25-38 µg/dL):
* More overt clinical signs such as PU/PD, weight loss, lethargy, decreased appetite, and intermittent vomiting are common.
* Aggressive Renal Diet & Phosphate Management: As per Stage II, but often requiring more strict adherence or higher doses of phosphate binders.
* Fluid Therapy: Subcutaneous fluid therapy (e.g., LRS, 50-100 mL/day or every other day) is often indicated to maintain hydration and renal perfusion, especially if the cat is not eating/drinking well or is clinically dehydrated.
* Anemia Management: Monitor PCV. If non-regenerative anemia develops (PCV <20-25%), consider darbepoetin alpha if iron stores are adequate.
* Potassium Management: Monitor serum potassium. Hypokalemia is common; supplement with potassium gluconate if needed.
* Metabolic Acidosis: Monitor TCO2/bicarbonate. If acidosis is persistent and symptomatic, consider oral alkalinizing agents (e.g., potassium citrate).
* Proteinuria/Hypertension: Critical management as per substaging guidelines below.
* IRIS Stage IV (Creatinine >5.0 mg/dL, SDMA >38 µg/dL):
* Severe clinical signs, often in uremic crisis.
* Intensive supportive care, often requiring hospitalization for IV fluids.
* Aggressive management of all complications (anemia, hypokalemia, metabolic acidosis, vomiting, anorexia).
* Consider advanced therapies like renal dialysis or transplantation if available and owner-elected.

Specific Treatment for Your Patient (IRIS Stage III, P, H)

Given your patient's IRIS Stage III, Proteinuric, and Hypertensive status, here's an evidence-based approach:

Dietary Management:

* Immediately transition to a therapeutic renal diet. This is foundational. If the cat is a finicky eater, try several brands/flavors.
Rationale:* Renal diets restrict phosphorus (proven to slow CKD progression) and protein (reduces uremic toxins, beneficial for proteinuria), and are alkalinizing.

Phosphate Management:

* Monitor serum phosphorus. If it's elevated (typically >4.5 mg/dL), start a phosphate binder.
* Drug: Aluminum hydroxide (e.g., 50-100 mg per meal, titrated to keep phosphorus <4.5 mg/dL). Always administer with food.
Rationale:* Hyperphosphatemia contributes significantly to CKD progression and secondary renal hyperparathyroidism.

Proteinuria Management:

* With a UPC of 0.6, intervention is warranted.
* Drug: Telmisartan (Semintra®) is generally preferred in cats for its consistent efficacy and palatability. Start at 1 mg/kg PO q24h. Alternatively, benazepril (an ACE inhibitor) can be used at 0.25-0.5 mg/kg PO q24h.
* Monitoring: Recheck creatinine, potassium, and blood pressure 5-7 days after starting to monitor for adverse effects (e.g., azotemia worsening, hyperkalemia, hypotension). Recheck UPC in 4-6 weeks aiming for a 25-50% reduction.
Rationale:* Proteinuria is an independent risk factor for CKD progression and is associated with tubulointerstitial damage. Reducing it helps preserve renal function.

Hypertension Management:

* With a BP of 170/95 mmHg, this cat is hypertensive and at risk for target organ damage (retinal detachment, CNS signs, further renal damage).
* Drug: Amlodipine is the first-line choice for feline hypertension. Start at 0.625 mg PO q24h.
* Monitoring: Recheck blood pressure in 7-10 days to assess response and titrate dose as needed (can increase to 1.25 mg q24h if BP remains uncontrolled).
Rationale:* Controlling hypertension protects target organs and helps slow CKD progression.

Hydration Support:

* Consider initiating subcutaneous fluids (e.g., Lactated Ringer's Solution) at 50-100 mL once daily or every other day, especially if the cat shows signs of dehydration, reduced appetite, or persistent azotemia despite oral intake.
Rationale:* Maintaining hydration and renal perfusion is critical in CKD patients.

Other Potential Interventions (based on monitoring):

* Monitor for anemia (PCV <25% in Stage III).
* Monitor for hypokalemia (serum K+ <3.5 mEq/L). Supplement with potassium gluconate (e.g., 2-5 mEq/day) if present.
* Monitor for metabolic acidosis (TCO2 <18 mEq/L).
* Manage any GI upset (vomiting, nausea) with antiemetics (e.g., maropitant 1 mg/kg PO/SQ q24h).

This is a complex patient requiring a multi-faceted approach. Close monitoring (initially every 2-4 weeks, then every 3 months once stable) of renal parameters (creatinine, SDMA, phosphorus, potassium), blood pressure, and UPC is essential to adjust therapy.

High confidence in this assessment and recommended protocol. Let me know if you have further questions or specific lab values to refine the plan.